ALX ONCOLOGY HOLDINGS INC (ALXO) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-13

Key Insights

ALX Oncology Holdings Inc. has appointed Jeff Knight as its new Chief Development and Operating Officer, bringing extensive experience in portfolio management, strategy, and operations from his previous roles at Crinetics Pharmaceuticals, Poseida Therapeutics, and other leading biopharmaceutical companies.
The employment offer letter provides Mr. Knight with a competitive compensation package, including an annual base salary of $565,000, a target cash bonus of 40% of his base salary, and a stock option grant of 800,000 shares vesting over four years.
The appointment of an experienced and seasoned executive like Jeff Knight to a key leadership role could signal the company's commitment to advancing its drug development pipeline and operational execution as it seeks to drive long-term growth and shareholder value.

Want the newest filings?

This analysis covers the filing from 2026-04-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-30

The company is conducting a public offering to raise approximately $150 million in gross proceeds, which could provide additional capital to fund its operations and development activities.
The offering includes the issuance of 76,979,112 shares of common stock and 18,574,120 pre-funded warrants, providing investors with flexibility in their investment approach.
The pre-funded warrants have customized terms, including limitations on the percentage of ownership that can be acquired, which may be of interest to certain investors.

Filed: 2026-01-30

The company announced positive data from a Phase 1b/2 clinical trial evaluating its investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' ZIIHERA® (zanidatamab-hrii) in heavily pretreated patients with metastatic breast cancer. The topline findings indicate that CD47 expression is predictive of evorpacept activity in patients with confirmed HER2-positive metastatic breast cancer.
The company disclosed preliminary unaudited financial information, estimating that it had approximately $48.3 million of cash and cash equivalents and short-term and long-term investments as of December 31, 2025. However, this estimate is subject to change upon completion of the company's financial statement closing procedures.
The company cautioned that the preliminary financial information has not been audited, does not present all necessary information for a complete understanding of the company's financial position, and is subject to change.

Filed: 2026-01-21

ALX Oncology Holdings Inc. has amended its 2025 Inducement Equity Incentive Plan to increase the number of shares reserved for issuance under the plan by 1,300,000 shares.
The amendment to the Inducement Plan was adopted by the Board of Directors without stockholder approval, as permitted by the Nasdaq Stock Market's inducement award exception.
The Inducement Plan provides for the grant of equity-based awards to individuals who are not previously employees or non-employee directors of the company, as an inducement for them to join the company.

Other reports for ALX ONCOLOGY HOLDINGS INC

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.